Health Care · Biotechnology
Regeneron Pharmaceuticals: revenue, profit and dividends
In fiscal 2025, Regeneron Pharmaceuticals had revenue of $14.3B, up 13.3% a year on average since 2015, and net income of $4.5B (31.4% of revenue). It paid a dividend of $3.52 a share. It has 6% fewer shares than in 2015.
Revenue, fiscal 2025
average annual revenue growth since 2015 · +1.0% vs 2024
- Ticker
- REGN · Nasdaq
- Sector
- Health Care
- Sub-industry
- Biotechnology
- Headquarters
- Tarrytown, New York
- Founded
- 1988
- In the S&P 500 since
- May 1, 2013
- Latest fiscal year
- 2025, ended December 31, 2025
- SEC filer
- Regeneron Pharmaceuticals, Inc. · CIK 0000872589
Revenue and net income
Revenue went from $238M in 2008 to $14.3B in 2025. Net loss in 2008–2011.
Diluted earnings per share
Diluted EPS went from −$0.85 in 2009 to $41.48 in 2025. Ten-year growth: 22.3% a year.
Shares outstanding
5.8% fewer shares in 2025 than in 2015 (115M → 109M): buybacks outweighed new shares.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was $4.08B in 2025, 28.4% of revenue. Negative in 2008–2012.
The chart data could not be loaded. The table below has the same figures.
Year by year
| Fiscal year | Revenue | Net income | Net margin | Diluted EPS | Dividend | Shares | Operating cash flow | Capex | Free cash flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $14.3B | $4.5B | 31.4% | $41.48 | $3.52* | 109M | $4.98B | $898M | $4.08B |
| 2024 | $14.2B | $4.41B | 31.1% | $38.34 | — | 115M | $4.42B | $756M | $3.66B |
| 2023 | $13.1B | $3.95B | 30.1% | $34.77 | — | 114M | $4.59B | $719M | $3.88B |
| 2022 | $12.2B | $4.34B | 35.6% | $38.22 | — | 114M | $5.01B | $590M | $4.42B |
| 2021 | $16.1B | $8.08B | 50.2% | $71.97 | — | 112M | $7.08B | $552M | $6.53B |
| 2020 | $8.5B | $3.51B | 41.3% | $30.52 | — | 115M | $2.62B | $615M | $2.0B |
| 2019 | $6.56B | $2.12B | 32.3% | $18.46 | — | 115M | $2.43B | $430M | $2.0B |
| 2018 | $5.15B | $2.44B | 47.5% | $21.29 | — | 115M | $2.2B | $383M | $1.81B |
| 2017 | $5.87B | $1.2B | 20.4% | $10.34 | — | 116M | $1.31B | $273M | $1.03B |
| 2016 | $4.86B | $896M | 18.4% | $7.70 | — | 116M | $1.49B | $512M | $974M |
| 2015 | $4.1B | $636M | 15.5% | $5.52 | — | 115M | $1.33B | $678M | $653M |
| 2014 | $2.82B | $338M | 12.0% | $2.98 | — | 113M | $752M | $333M | $419M |
| 2013 | $2.1B | $414M | 19.7% | $3.72 | — | 111M | $589M | $156M | $432M |
| 2012 | $1.38B | $750M | 54.4% | $6.75 | — | 115M | −$74.6M | $49.3M | −$124M |
| 2011 | $446M | −$222M | −49.7% | −$2.45 | — | 90.6M | −$142M | $57.2M | −$199M |
| 2010 | $459M | −$104M | −22.8% | −$1.26 | — | 82.9M | $99.2M | $99.7M | −$467K |
| 2009 | $379M | −$67.8M | −17.9% | −$0.85 | — | — | −$69.9M | $97.3M | −$167M |
| 2008 | $238M | −$79.1M | −33.2% | — | — | — | −$89.1M | $34.9M | −$124M |
Fiscal years, labelled by the year in which they end. US dollars; per-share figures and share counts adjusted for splits. —: not in the data. * added up from quarterly reports.
About these figures
- Dividends per share for 2025 are added up from the quarterly reports.
- Older years are as filed at the time and may predate later restatements, mergers or spin-offs. How the figures are made.
Other Biotechnology companies
Source: SEC EDGAR (company filings), data as of November 8, 2026. Sectors, sub-industries, headquarters and index dates: Wikipedia, CC BY-SA 4.0.